Microbubbles are tiny gas-filled spheres that could revolutionize drug delivery in medicine, particularly for hard-to-reach areas like the brain. Traditional methods of delivering drugs often fail to reach their intended targets; for instance, less than one percent of injected cancer drugs may reach the tumor. The blood-brain barrier complicates this further, blocking most large drugs and many small molecules, making conditions like epilepsy and Alzheimer's notoriously difficult to treat. Microbubbles could potentially burst open these barriers, allowing drugs to penetrate where they otherwise can’t. The development of microbubbles began in the late 1960s with a serendipitous discovery during ultrasound imaging. Researchers found that injecting saline created bright signals due to tiny air bubbles. Over time, medical microbubbles were engineered to have stable outer shells made from lipids, proteins, or polymers. One notable example is Albunex, which was approved by the FDA in the early 1990s for cardiac ultrasounds and utilized albumin to create a stable microsphere. Modern microbubbles can use heavier gases to prolong their lifespan in blood circulation, enhancing their applicability in imaging. Microbubbles offer more than just imaging capabilities; they can expand, contract, and burst due to a phenomenon known as cavitation. This process can temporarily open blood vessel walls and create small pores in cell membranes, a method called sonoporation. This could allow drugs to pass through the blood-brain barrier without causing permanent damage. Researchers have also explored steering microbubbles to specific locations by attaching magnetic nanoparticles, effectively controlling where the drug is delivered within the body. Despite their potential, therapeutic microbubbles have not yet received regulatory approval, primarily due to the complexities in testing their effectiveness compared to imaging bubbles already in use.